https://www.thebodypro.com/author/david-alain-wohl

Latest by David Alain Wohl, M.D.

ending the us epidemic photo illo
Features

The Ironies of a New Plan to End the U.S. HIV Epidemic

The attention of this specific U.S. president on HIV is curious. However, while it may be initially disorienting, it makes sense, explains David Wohl, M.D.

In 2013, The New and Observer cover featuring Dr. Charles Van Der Horst getting arrested during a protest
Features

A Final Tribute to Charles van der Horst

Although you may not have known -- or even heard of -- Charles van der Horst, his DNA is woven into the cloth of HIV care and research.

GEMINI and the Rise of Two-Drug HIV Therapy: A Top HIV Clinical Development of 2018 Img

GEMINI and the Rise of Two-Drug HIV Therapy: A Top HIV Clinical Development of 2018

The concept of a three-drug minimum for HIV therapy is rooted in a sequentialism that emerged with the dawning of antiretroviral treatment: one drug = nothing; two drugs = meh; three drugs = bingo! Over the years, in an effort to avoid peskier antire...

Debate Over Dolutegravir in Early Pregnancy: A Top HIV Clinical Development of 2018 Img

Debate Over Dolutegravir in Early Pregnancy: A Top HIV Clinical Development of 2018

In 2018, the same year we learned that a two-drug initial HIV treatment regimen featuring dolutegravir (Tivicay, DTG) was viable for many of our patients, we also got a much-less-welcome dolutegravir (Tivicay, DTG)-related surprise. Early in the year...

Integrase Inhibitors and Weight Gain: A Top HIV Clinical Development of 2018 Img

Integrase Inhibitors and Weight Gain: A Top HIV Clinical Development of 2018

Integrase inhibitors have revolutionized HIV treatment, as a glance at HIV treatment guidelines over the past few years makes clear. And with good reason: They're well tolerated, have a high barrier to resistance, and are potent as all get out. But t...

PrEP and the Decline in New HIV Diagnoses: A Top HIV Clinical Development of 2018 Img

PrEP and the Decline in New HIV Diagnoses: A Top HIV Clinical Development of 2018

Fact #1: New diagnoses of HIV dropped by almost 20% from 2008 to 2015. Fact #2: Pre-exposure prophylaxis (PrEP) uptake increased dramatically during the same period.

Cause and effect or happy accident? A team from Emory University and the neighborin...

On-Demand Prevention in France: A Top HIV Clinical Development of 2018 Img

On-Demand Prevention in France: A Top HIV Clinical Development of 2018

We know HIV pre-exposure prophylaxis (PrEP) works, but is daily dosing really necessary? For many, the dictum of a "pill a day keeps the HIV away" is just fine. Yet, some have a harder time taking medications daily.

A few years ago, the IPERGAY stud...

Bictegravir Has Finally Arrived: A Top HIV Clinical Development of 2018 Img

Bictegravir Has Finally Arrived: A Top HIV Clinical Development of 2018

I had to double check that it really was earlier this year that bictegravir was U.S. Food and Drug Administration-approved. On Feb. 7, the approval of the fixed-dose formulation of bictegravir with tenofovir alafenamide fumarate and emtricitabine (Bi...

Abacavir, Platelets, and a Cardiovascular Verdict: A Top HIV Clinical Development of 2018 Img
Cardiovascular

Abacavir, Platelets, and a Cardiovascular Verdict: A Top HIV Clinical Development of 2018

Debates about the role of abacavir (Ziagen, ABC) in the development of cardiovascular disease in persons living with HIV have raged for over a decade, and a kind of stalemate has been achieved between those who are and are not convinced of a link. Wh...

African-American Men and HIV Treatment Outcomes: A Top HIV Clinical Development of 2018 Img
African-Americans

African-American Men and HIV Treatment Outcomes: A Top HIV Clinical Development of 2018

The HIV pandemic, like the virus itself, is opportunistic and parasitic. AIDS is a disease of poverty, disruption, stigma, and chaos. Wherever the social fabric is torn, HIV enters and occupies. Wherever communities struggle, HIV thrives. Here in the...